News
TAK
15.98
+0.44%
0.07
Takeda Updates Articles of Incorporation in June 2026 SEC Filing
TipRanks · 21h ago
Weekly Report: what happened at TAK last week (0622-0626)?
Weekly Report · 23h ago
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
NASDAQ · 3d ago
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Seeking Alpha · 3d ago
Takeda Shareholders Approve Dividend and Board Slate at 150th Annual Meeting
TipRanks · 3d ago
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Benzinga · 5d ago
Takeda Appoints Julie Kim President & CEO Following 18-Month Transition As Weber Retires
NASDAQ · 5d ago
Takeda Names Julie Kim CEO As Christophe Weber Retires
NASDAQ · 5d ago
Takeda finalizes 18-month transition: Julie Kim officially appointed President & CEO
Seeking Alpha · 6d ago
TAKEDA ANNOUNCES NEW ASSIGNMENTS OF DIRECTORS AND APPOINTMENT OF JULIE KIM AS REPRESENTATIVE DIRECTOR, PRESIDENT AND CEO
Reuters · 6d ago
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
TipRanks · 6d ago
Takeda Canada Announces Positive Topline Results For Phase 3 LATITUDE Atlas Study For Psoriasis
NASDAQ · 6d ago
Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis
Benzinga · 6d ago
TAKEDA PHARMACEUTICAL CO - TO SUBMIT NEW DRUG APPLICATION FOR ZASOCITINIB STARTING THIS FISCAL YEAR
Reuters · 6d ago
Dyne Therapeutics appoints former Sage CEO Barry Greene to board
PUBT · 06/22 20:10
Weekly Report: what happened at TAK last week (0615-0619)?
Weekly Report · 06/22 09:15
Takeda’s New Polish Study Tracks Real-World Impact of Fruquintinib in Advanced Colorectal Cancer
TipRanks · 06/18 16:35
Takeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks
TipRanks · 06/18 06:00
Takeda Releases New Positive Phase 3 FirstLight And RadiantLight Data For Oveporexton In Narcolepsy
NASDAQ · 06/16 07:46
Takeda: Oveporexton Improves Daily Function, Cognition, Nighttime Sleep In Narcolepsy Type 1
NASDAQ · 06/16 05:42
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.